A Novel Epithelial-mesenchymal Transition Gene Signature for the Immune Status and Prognosis of Hepatocellular Carcinoma

Overview

Journal Hepatol Int

Publisher Springer

Specialty Gastroenterology

Date 2022 Jun 14

PMID 35699863

Authors

Yanlong Shi

Jingyan Wang

Guo Huang

Jun Zhu

Haokun Jian

Guozhi Xia

Qian Wei

Yuanhai Li

Hongzhu Yu

Affiliations

Soon will be listed here.

Abstract

Background: This study clarified whether EMT-related genes can predict immunotherapy efficacy and overall survival in patients with HCC.

Methods: The RNA-sequencing profiles and patient information of 370 samples were derived from the Cancer Genome Atlas (TCGA) dataset, and EMT-related genes were obtained from the Molecular Signatures database. The signature model was constructed using the least absolute shrinkage and selection operator Cox regression analysis in TCGA cohort. Validation data were obtained from the International Cancer Genome Consortium (ICGC) dataset of patients with HCC. Kaplan-Meier analysis and multivariate Cox analyses were employed to estimate the prognostic value. Immune status and tumor microenvironment were estimated using a single-sample gene set enrichment analysis (ssGSEA). The expression of prognostic genes was verified using qRT-PCR analysis of HCC cell lines.

Results: A signature model was constructed using EMT-related genes to determine HCC prognosis, based on which patients were divided into high-risk and low-risk groups. The risk score, as an independent factor, was related to tumor stage, grade, and immune cells infiltration. The results indicated that the most prognostic genes were highly expressed in the HCC cell lines, but GADD45B was down-regulated. Enrichment analysis suggested that immunoglobulin receptor binding and material metabolism were essential in the prognostic signature.

Conclusion: Our novel prognostic signature model has a vital impact on immune status and prognosis, significantly helping the decision-making related to the diagnosis and treatment of patients with HCC.

Citing Articles

Contradictory Role of Gadd45β in Liver Diseases.

Wu C, Song X, Zhang M, Yang L, Lu P, Ding Q J Cell Mol Med. 2024; 28(23):e70267.

PMID: 39653679 PMC: 11628191. DOI: 10.1111/jcmm.70267.

Hepatocellular-Carcinoma-Derived Organoids: Innovation in Cancer Research.

Airola C, Pallozzi M, Cesari E, Cerrito L, Stella L, Sette C Cells. 2024; 13(20.

PMID: 39451244 PMC: 11505656. DOI: 10.3390/cells13201726.

NCAPD2 serves as a potential prognostic biomarker for lung adenocarcinoma and promotes cell proliferation, migration, invasion and cell cycle .

Wu P, Zhao L, Zhang H, Lou Y, Chen D, Xue S Oncol Res. 2024; 32(9):1439-1452.

PMID: 39220139 PMC: 11361896. DOI: 10.32604/or.2024.047490.

Dual-Drug Loaded Nanobubbles Combined with Sonodynamic and Chemotherapy for Hepatocellular Carcinoma Therapy.

Guo T, Wang Y, Chen D, Cui S, Guo S, Feng Y Int J Nanomedicine. 2024; 19:7367-7381.

PMID: 39050872 PMC: 11268764. DOI: 10.2147/IJN.S460329.

Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma.

Liu Z, Yang L, Liu C, Wang Z, Xu W, Lu J Front Immunol. 2024; 15:1371829.

PMID: 38933262 PMC: 11199539. DOI: 10.3389/fimmu.2024.1371829.

References

Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

Shibue T, Weinberg R . EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017; 14(10):611-629. PMC: 5720366. DOI: 10.1038/nrclinonc.2017.44. View

Liebermann D, Tront J, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B . Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 2011; 16(1-2):129-40. PMC: 3268054. DOI: 10.1615/critrevoncog.v16.i1-2.120. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Lei X, Lei Y, Li J, Du W, Li R, Yang J . Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2019; 470:126-133. DOI: 10.1016/j.canlet.2019.11.009. View

Lin Z, Xu Q, Miao D, Yu F . An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Front Oncol. 2021; 11:644416. PMC: 8019928. DOI: 10.3389/fonc.2021.644416. View

Castello L, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M . Osteopontin at the Crossroads of Inflammation and Tumor Progression. Mediators Inflamm. 2017; 2017:4049098. PMC: 5523273. DOI: 10.1155/2017/4049098. View

Yu C, Yu Y, Yang S, Hsu C, Lin C, Hsieh Y . Praeruptorin A reduces metastasis of human hepatocellular carcinoma cells by targeting ERK/MMP1 signaling pathway. Environ Toxicol. 2020; 36(4):540-549. DOI: 10.1002/tox.23059. View

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

10.

Giannini E, Aglitti A, Borzio M, Gambato M, Guarino M, Iavarone M . Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. Cancers (Basel). 2019; 11(11). PMC: 6896125. DOI: 10.3390/cancers11111689. View

11.

Chan T, Lin C, Qi L, Fei J, Li Y, Yong K . A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut. 2013; 63(5):832-43. PMC: 3995272. DOI: 10.1136/gutjnl-2012-304037. View

12.

DiStefano J, Davis B . Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4). PMC: 6521254. DOI: 10.3390/cancers11040486. View

13.

Pereira M, Barros L, Bracco P, Vigo A, Boroni M, Bonamino M . Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival. Oncoimmunology. 2018; 7(6):e1431083. PMC: 5980418. DOI: 10.1080/2162402X.2018.1431083. View

14.

Xiao T, Zhang Q, Zong S, Zhong W, Qin Y, Bi Z . Protease-activated receptor-1 (PAR1) promotes epithelial-endothelial transition through Twist1 in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018; 37(1):185. PMC: 6091192. DOI: 10.1186/s13046-018-0858-4. View

15.

Xiao Y, Li Y, Tao H, Humphries B, Li A, Jiang Y . Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Lett. 2018; 433:199-209. DOI: 10.1016/j.canlet.2018.06.037. View

16.

Sanghera C, Teh J, Pinato D . The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma. Liver Int. 2019; 39(11):2008-2023. DOI: 10.1111/liv.14220. View

17.

Tao L, Shu-Ling W, Jing-Bo H, Ying Z, Rong H, Xiang-Qun L . MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc. Biomed Pharmacother. 2020; 125:109962. DOI: 10.1016/j.biopha.2020.109962. View

18.

Barros-Filho M, de Mello J, Marchi F, Pinto C, da Silva I, Damasceno P . GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy. Front Endocrinol (Lausanne). 2020; 11:269. PMC: 7203742. DOI: 10.3389/fendo.2020.00269. View

19.

Jiang Y, Xie J, Han Z, Liu W, Xi S, Huang L . Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. Clin Cancer Res. 2018; 24(22):5574-5584. DOI: 10.1158/1078-0432.CCR-18-0848. View

20.

Guerriero E, Capone F, Accardo M, Sorice A, Costantini M, Colonna G . GPX4 and GPX7 over-expression in human hepatocellular carcinoma tissues. Eur J Histochem. 2015; 59(4):2540. PMC: 4698610. DOI: 10.4081/ejh.2015.2540. View